Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Wu, Z., & McGoogan, J. M. (2020) · JAMA · doi:10.1001/jama.2020.2648 · Cited by 17,016

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury

Kuba, K., Imai, Y., Rao, S., Gao, H., Guo, F., Guan, B., Huan, Y., Yang, P., Zhang, Y., Deng, W., et al. (2005) · Nature Medicine · doi:10.1038/nm1267 · Cited by 3,445

Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury

Liu, Y., Yang, Y., Zhang, C., Huang, F., Wang, F., Yuan, J., Wang, Z., Li, J., Li, J., Feng, C., et al. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1643-8 · Cited by 2,056

Status of Hypertension in China: Results From the China Hypertension Survey, 2012–2015

Wang, Z., Chen, Z., Zhang, L., Wang, X., Hao, G., Zhang, Z., Shao, L., Tian, Y., Dong, Y., Zheng, C., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.032380 · Cited by 1,698

Addendum: A pneumonia outbreak associated with a new coronavirus of probable bat origin

Zhou, P., Yang, X., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2951-z · Cited by 715

Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury

Yang, P., Gu, H., Zhao, Z., Wang, W., Cao, B., Lai, C., Yang, X., Zhang, L., Duan, Y., Zhang, S., et al. (2014) · Scientific Reports · doi:10.1038/srep07027 · Cited by 283

ACE2 exhibits protective effects against LPS-induced acute lung injury in mice by inhibiting the LPS-TLR4 pathway

Ye, R., & Liu, Z. (2019) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2019.104350 · Cited by 205

Beta Blocker and Angiotensin-Converting Enzyme Inhibitor Therapy Is Associated with Decreased Th1/Th2 Cytokine Ratios and Inflammatory Cytokine Production in Patients with Chronic Heart Failure

Gage, J. R., Fonarow, G. C., Hamilton, M. A., Widawski, M., Martı́nez-Maza, O., & Vredevoe, D. L. (2004) · NeuroImmunoModulation · doi:10.1159/000076766 · Cited by 81

Recent Update of Renin-angiotensin-aldosterone System in the Pathogenesis of Hypertension

Moon, J.-Y. (2013) · Electrolytes & Blood Pressure · doi:10.5049/ebp.2013.11.2.41 · Cited by 81

Lisinopril increases lung ACE2 levels and SARS-CoV-2 viral load and decreases inflammation but not disease severity in experimental COVID-19

Santos, Y. D. S., Pagni, R. L., Gamon, T. H. M., de Azevedo, M. S. P., Bielavsky, M., Darido, M. L. G., Oliveira, D. B. L., de Souza, E. E., Wrenger, C., Durigon, E. L., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1414406 · Cited by 6

Renin-angiotensin system modulators in COVID-19 patients with hypertension: friend or foe?

Shylesh, S., S, A. V., Kanthlal, S. K., & Uma Devi, P. (2021) · Clinical and Experimental Hypertension · doi:10.1080/10641963.2021.1963070 · Cited by 6

Ramipril Reduces Acylcarnitines and Distinctly Increases Angiotensin-Converting Enzyme 2 Expression in Lungs of Rats

Kosacka, J., Berger, C., Ceglarek, U., Hoffmann, A., Blüher, M., & Klöting, N. (2022) · Metabolites · doi:10.3390/metabo12040293 · Cited by 6

Characterization of the angiotensin-converting enzyme 2 (ACE2), the main receptor for the SARS-CoV-2 virus.

Jami, G., Ataee, M., Esmaeili, V., Chamani, S., Rezaei, A., & Naghizadeh, A. (2023) · PubMed Central · Cited by 6

Understanding Gender-Bias in Critically Ill Patients With COVID-19

Chamekh, M., & Casimir, G. J. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.564117 · Cited by 6

Use of Renin-Angiotensin-Aldosterone System Inhibitors and Severe COVID-19 Outcomes in Patients with Hypertension: A Nationwide Cohort Study

Bae, J. H., Choi, S. K., Kim, N. H., Lee, J., & Kim, S. G. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0279 · Cited by 6

The Effects of ATIR Blocker on the Severity of COVID-19 in Hypertensive Inpatients and Virulence of SARS-CoV-2 in Hypertensive hACE2 Transgenic Mice

Jiang, X., Li, H., Liu, Y. H., Bao, L., Zhan, L., Gao, H., Deng, W., Xue, J., Liu, J., Liu, X., et al. (2022) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-021-10147-3 · Cited by 6

Heart Failure Relapses in Response to Acute Stresses – Role of Immunological and Inflammatory Pathways

Hasselbach, L., Weidner, J., Elsässer, A., & Theilmeier, G. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.809935 · Cited by 8

Angiotensin Converting Enzyme 2 in Coronavirus Disease (COVID-19): Evidence from Bioinformatics AnalysisPreprint

Yang, X., Zhao, H., Li, Y., & Zhang, P. (2020) · Preprints.org · doi:10.20944/preprints202004.0466.v1 · Cited by 5

Association between angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers use and the risk of infection and clinical outcome of COVID-19: a comprehensive systematic review and meta-analysisPreprint

Qu, G., Shu, L., Song, E. J., Verghese, D., Uy, J. P., Cheng, C., Zhou, Q., Yang, H., Guo, Z., Chen, M., et al. (2020) · medRxiv · doi:10.1101/2020.07.02.20144717 · Cited by 6

Could a specific ACE2 activator drug improve the clinical outcome of SARS-CoV-2? A potential pharmacological insight

Nicolau, L. A. D., Nolêto, I. R. D. S. G., & Medeiros, J. V. R. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1798760 · Cited by 6

Association of Renin-Angiotensin System Blockers With Outcomes in Patients with COVID-19

Garg, A., Rout, A., Sharma, A., Fiorello, B., & Kostis, J. B. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.09.010 · Cited by 6

IN-HOSPITAL CONTINUATION WITH ANGIOTENSIN RECEPTOR BLOCKERS IS ASSOCIATED WITH A LOWER MORTALITY RATE THAN CONTINUATION WITH ANGIOTENSIN CONVERTING ENZYME INHIBITORS IN COVID-19 PATIENTS: A RETROSPECTIVE COHORT STUDYPreprint

de Abajo, F. J., Rodríguez-Miguel, A., Rodríguez‐Martín, S., Lerma, V., & García‐Lledó, A. (2021) · medRxiv · doi:10.1101/2021.02.01.21250853 · Cited by 6

A potential therapeutic combination for treatment of COVID-19: Synergistic effect of DPP4 and RAAS suppression

Khin, P. P., Cha, S., Jun, H., & Lee, J. H. (2020) · Medical Hypotheses · doi:10.1016/j.mehy.2020.110186 · Cited by 5

ACEI/ARB drug therapy in COVID-19 patients: Yes or no?

Gong, J., Sun, Y., & Xie, L. (2021) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2021-0011 · Cited by 5

Food-Derived Bioactive Peptides: A Promising Substitute to Chemosynthetic Drugs Against the Dysregulated Renin-Angiotensin System in COVID-19 Patients

Mahamud, A. G. M. S. U., Kabir, M. E., Sohag, A. A. M., Chen, C., Hannan, M. A., Sikder, M. H., Bhattarai, K., Baral, B., & Uddin, M. J. (2021) · Journal of Biologically Active Products from Nature · doi:10.1080/22311866.2021.1945494 · Cited by 5

Risk Factors Associated with the Clinical Outcomes of COVID-19 and Its Variants in the Context of Cytokine Storm and Therapeutics/Vaccine Development Challenges

Hanna, J. J., Tipparaju, P., Mulherkar, T., Lin, E., Mischley, V., Kulkarni, R., Bolton, A. I., Byrareddy, S. N., & Jain, P. (2021) · Vaccines · doi:10.3390/vaccines9080938 · Cited by 5

Damage to the Vascular Endothelium as a Leading Mechanism of COVID-19 Systemic Pathology

Гомазков, О. А. (2021) · Biology Bulletin Reviews · doi:10.1134/s2079086421060049 · Cited by 5

Interaction of ACEI antihypertensive agent's administration with the inflammatory status at admission concerning COVID-19 clinical stay outcomes

Martínez‐Urbistondo, M., Moreno‐Torres, V., Vargas, A. M., Expósito-Palomo, E., Castejón, R., Daimiel, L., Ramos-López, O., San-Cristóbal, R., Vargas, J. A., & Martínez, J. A. (2022) · Vascular Pharmacology · doi:10.1016/j.vph.2022.106955 · Cited by 5

Host-Cell Surface Binding Targets in SARS-CoV-2 for Drug Design

Tabatabai, S. A., Maleksabet, H., & Rezaee, E. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612829666221123111849 · Cited by 5

Recent Insights on Drug Delivery System in Hypertension: From Bench to Market

Sharma, G., & Sharma, A. (2023) · Current Hypertension Reviews · doi:10.2174/1573402119666230707120846 · Cited by 5

Long-term oral ACEI/ARB therapy is associated with disease severity in elderly COVID-19 omicron BA.2 patients with hypertension

Zhang, Z., Wu, S. Y., Wang, Z., Wang, Y., Chen, H., Wu, C., & Xiong, L. (2023) · BMC Infectious Diseases · doi:10.1186/s12879-023-08913-6 · Cited by 5

Drug prescription patterns and their association with mortality and hospitalization duration in COVID-19 patients: insights from big data

Mehrizi, R., Golestani, A., Malekpour, M., Karami, H., Nasehi, M. M., Effatpanah, M., Ranjbaran, H., Shahali, Z., Sari, A. A., & Daroudi, R. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1280434 · Cited by 5

The SARS-COV2 (COVID-19) Pandemic: What Clinicians should knew

Saeed, M., Zaher, T. I., Khorshed, S. E., Saraya, M. A., Mahmoud, T., Emara, M., Mahrous, A., Ahmed, N. H., Khattab, F. M., Abdelmaksoud, M. A., et al. (2020) · Afro-Egyptian Journal of Infectious and Endemic Diseases · doi:10.21608/aeji.2020.93424 · Cited by 5

COVID-19: A Concern for Cardiovascular Disease Patients

Sharma, S. (2020) · Cardiovascular Toxicology · doi:10.1007/s12012-020-09596-0 · Cited by 5

Screening druggable targets and predicting therapeutic drugs for COVID-19 via integrated bioinformatics analysis

Tan, S., Chen, W., Xiang, H., Kong, G., Zou, L., & Wei, L. (2021) · Genes & Genomics · doi:10.1007/s13258-020-01021-8 · Cited by 5

Renin Angiotensin Aldosterone System Antagonism in 2019 Novel Coronavirus Acute Lung Injury

Ventura, D., Carr, A., Davis, R. D., Silvestry, S., Bogar, L. J., RAVAL, N. Y., Gries, C., Hayes, J. E., Oliveira, E., Sniffen, J. C., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab170 · Cited by 5

Hypothesis for renin-angiotensin inhibitor mitigation of COVID-19

Sackin, H. (2021) · Medical Hypotheses · doi:10.1016/j.mehy.2021.110609 · Cited by 5

Cardiovascular system and coronavirus disease-2019 (COVID-19): mutual injuries and unexpected outcomes

Sobh, E., Reihan, M. S., Hifnawy, T. M. S., Abdelsalam, K. G., Awad, S. S., Mahmoud, N. M. H., Sindi, N., & Alhadrami, H. A. (2021) · The Egyptian Heart Journal · doi:10.1186/s43044-021-00202-4 · Cited by 6

COVID-19 and RAAS inhibitors: is there a final conclusion?

Taher, M. T., Najafi, M. H., & Behzad, S. (2021) · Iranian Journal of Microbiology · doi:10.18502/ijm.v13i6.8071 · Cited by 5

Patients with severe COVID‐19 have reduced circulating levels of angiotensin‐(1–7): A cohort study

Seyedmehdi, S. M., Imanparast, F., Mohaghegh, P., Mahmoudian, S., Dehlaqi, M. K., Mehvari, F., & Abdullah, M. P. (2022) · Health Science Reports · doi:10.1002/hsr2.564 · Cited by 5

Pre-morbidity and COVID-19 disease outcomes in Pakistani population: A cross-sectional study

Toori, K. U., Qureshi, M. A., & Chaudhry, A. (2021) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.38.1.4235 · Cited by 5

SARS-CoV-2 infection disrupts syncytial and endothelial integrity and alters PLGF levels in the placenta

Jones, B. R., Nobrega, G. D. M., Kumar, D., Diveley, E., Antolini‐Tavares, A., Souza, R. T., Cecatti, J. G., Kelly, J. C., Costa, M. L., & Mysorekar, I. U. (2025) · Placenta · doi:10.1016/j.placenta.2025.09.009 · Cited by 4

Pharmacotherapeutic agents for the management of COVID-19 patients with preexisting cardiovascular disease

Khan, M. A., Singh, G. K., Abrar, S., Ganeshan, R., Morgan, K., & Harky, A. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1960311 · Cited by 5

COVID-19 Pandemic Waves and 2024–2025 Winter Season in Relation to Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers and Amantadine

Puigdellívol‐Sánchez, A., Juanes-González, M., Calderón-Valdiviezo, A., Losa-Puig, H., González-Salvador, M., León-Pérez, M., Pueyo-Antón, L., Franco-Romero, M., Lozano-Paz, C., Borra, A. C., et al. (2025) · Healthcare · doi:10.3390/healthcare13111270 · Cited by 4

Role of the renin-angiotensin-aldosterone system in sepsis and its therapeutic targets

Chen, X., Shao, M. L., Liu, Y., Zhou, J., Cao, F., Liu, Y., Qiu, G., Jiang, T., Huang, M., & Zhang, L. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115192 · Cited by 5

COVID-19 Incidence in Patients With Immunomediated Inflammatory Diseases: Influence of Immunosuppressant Treatments

Soldevila‐Domenech, N., Tío, L., Llorente‐Onaindia, J., Martín‐García, E., Nebot, P., de la Torre, R., Gurt, A., Maldonado, R. J., Monfort, J., & the Covidmar Study Group (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.583260 · Cited by 4

Different therapeutic associations of renin-angiotensin system inhibitors with coronavirus disease 2019 compared with usual pneumonia

Lee, H., Ahn, J., Park, J., Kang, C. K., Won, S., Kim, D. W., Park, J. H., Chung, K.-H., Joh, J.-S., Bang, J. H., et al. (2021) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2020.656 · Cited by 4

The COVID-19 pandemic, heart and cardiovascular diseases: What we have learned

Piątek, Z., Gać, P., & Poręba, M. (2021) · Dental and Medical Problems · doi:10.17219/dmp/133153 · Cited by 4

One Year of the COVID‐19 Pandemic. What Do We Know and What Is Yet to Come? — The Summarising Review

Malchrzak, W., Mastalerz–Migas, A., Sroka, Z., & Spiegel, M. (2021) · International Journal of Public Health · doi:10.3389/ijph.2021.1603975 · Cited by 4

Differentiated approach to treatment of cognitive disorders associated with SARS-CoV-2 (COVID-19), taking into account comorbidity factor

Putilina, M. V., Teplova, N. V., & Сергеевна, Г. О. (2021) · Medical alphabet · doi:10.33667/2078-5631-2021-22-18-24 · Cited by 4

Molecular Determinants, Clinical Manifestations and Effects of Immunization on Cardiovascular Health During COVID-19 Pandemic Era - A Review

Chatterjee, A., Saha, R., Mishra, A., Shilkar, D., Jayaprakash, V., Sharma, P. K., & Sarkar, B. (2022) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2022.101250 · Cited by 4

Impact of prior antihypertensive treatment on COVID-19 outcomes, by active ingredient

García-Álvarez, R. M., Zapata‐Cachafeiro, M., Visos‐Varela, I., Rodríguez-Fernández, A., Pintos‐Rodríguez, S., Piñeiro‐Lamas, M., Herdeiro, M. T., Figueiras, A., Salgado‐Barreira, Á., COVID-Drug Group, et al. (2024) · Inflammopharmacology · doi:10.1007/s10787-024-01475-2 · Cited by 4

Renin-angiotensin system modulators and other risk factors in COVID-19 patients with hypertension: a Korean perspective

Kim, H., Kang, M., & Kang, G. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-05848-8 · Cited by 4

The effect of RAAS inhibitors on acute hypoxemic respiratory failure and in-hospital mortality in the hypertensive Covid-19 patients

Akyüz, A., Işık, F., Aslan, B., Çap, M., Kaya, İ., Atlı, Ö., İnci, Ü., Taştan, E., Aktan, A., Bilge, Ö., et al. (2021) · Clinical and Experimental Hypertension · doi:10.1080/10641963.2021.1916947 · Cited by 4

COVID-19: Is it time to revisit the research on calcium channel drug targets?

Balasubramanyam, M. (2020) · EMJ Diabetes · doi:10.33590/emjdiabet/200608 · Cited by 4

Association of Renin Angiotensin System Blockers with Outcomes in Patients with Covid-19: A Systematic Review and Meta-analysisPreprint

Garg, A., Rout, A., Sharma, A., Fiorello, B., & Kostis, J. B. (2020) · medRxiv · doi:10.1101/2020.05.23.20111401 · Cited by 4

Association Between ACEIs or ARBs Use and Clinical Outcomes in COVID-19 Patients: A Systematic Review and Meta-analysisPreprint

Diaz‐Arocutipa, C., Saucedo‐Chinchay, J., & Hernández, A. V. (2020) · medRxiv · doi:10.1101/2020.06.03.20120261 · Cited by 4

Effect of Renin-Angiotensin-Aldosterone System inhibitors on outcomes of COVID-19 patients with hypertension: Systematic review and Meta-analysisPreprint

Beressa, T. B., Sahilu, T., & Deyno, S. (2020) · medRxiv · doi:10.1101/2020.09.03.20187393 · Cited by 4

Mortality and disease severity among COVID-19 patients with hypertension receiving renin-angiotensin system inhibitorsPreprint

Hasan, S. S., Kow, C. S., & Merchant, H. A. (2020) · doi:10.22541/au.158880148.84250526 · Cited by 4

COVID-19 and inhibitors of the renin–angiotensin–aldosterone system

Hussain, M., Jabeen, Q., Ahmad, F.-U.-D., Kashif-ur-Rehman, Fatima, M., Shaukat, S., Majeed, A., Barkat, M. Q., & Wu, X. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2021.1851197 · Cited by 4

Identification of pulmonary comorbid diseases network based repurposing effective drugs for COVID-19Preprint

Patel, J. C., Tulswani, R., Khurana, P., Sharma, Y. K., Ganju, L., Kumar, B., & Sugadev, R. (2020) · doi:10.21203/rs.3.rs-28148/v1 · Cited by 4

COVID-19 and the Use of Angiotensin II Receptor Blockers in Older Chronic Hypertensive Patients: Systematic Review and Meta-Analysis

Quesada-Caballero, M., Carmona-García, A., Chami-Peña, S., Albendín‐García, L., Membrive-Jiménez, C., Romero‐Béjar, J. L., & la Fuente, G. A. C. (2023) · Medicina · doi:10.3390/medicina59071200 · Cited by 3

Uso terapéutico de los inhibidores de la enzima convertidora de angiotensina en pacientes con COVID-19: las «dos caras de la moneda»

Vallejo-Ardila, D. L., Tamayo-Cáceres, Y. R., & Alí-Munive, A. (2020) · Revista Colombiana de Cardiología · doi:10.1016/j.rccar.2020.07.001 · Cited by 7

Severe COVID-19 infection: An institutional review and literature overview

Akpoviroro, O., Sauers, N. K., Queeneth, U., Castagne, M., Akpoviroro, O. P., Humayun, S., Mirza, W., & Woodard, J. (2024) · PLoS ONE · doi:10.1371/journal.pone.0304960 · Cited by 4

Relationship between angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and SARS-CoV-2 infection: where are we?

Infusino, F., Cimino, S., Lombardi, M., Mancone, M., Cavarretta, E., Frati, G., Pugliese, F. R., Fedele, F., & Biondi‐Zoccai, G. (2020) · Minerva Cardioangiologica · doi:10.23736/s0026-4725.20.05271-8 · Cited by 3

No harm from angiotensin-converting enzyme inhibitors or angiotensin receptor inhibitors in patients with COVID-19. Results of a prospective study on a hospital-based cohort

Anzola, G. P., Bartolaminelli, C., Gregorini, G. A., Coazzoli, C., Gatti, F., Mora, A., Charalampakis, D., Palmigiano, A., Simone, M. D., Comini, A., et al. (2020) · Italian Journal of Medicine · doi:10.4081/itjm.2020.1313 · Cited by 3

Renin-Angiotensin-Aldosterone System Blockers Prior to Hospitalization and Their Association With Clinical Outcomes in Coronavirus Disease 2019 (COVID-19)

Banwait, R., Singh, D., Blanco, A., Rastogi, V., & Abusaada, K. (2021) · Cureus · doi:10.7759/cureus.13429 · Cited by 3

Is treated hypertension associated with a lower one-year mortality among older residents of long-term care facilities with multimorbidity?

Kańtoch, A., Pac, A., Wizner, B., Wójkowska‐Mach, J., Heczko, P. B., Grodzicki, T. K., & Gryglewska, B. (2021) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.15944 · Cited by 3

Risk of Viral Infection in Patients Using Either Angiotensin-converting Enzyme Inhibitors or Angiotensin Receptor Blockers: A Nationwide Population-based Propensity Score Matching Study

Lin, S.-Y., Ju, S.-W., Lin, C., Lin, C., Hsu, W., Chou, C.-H., Chi, C.-Y., Hsu, C. Y., & Kao, C. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa734 · Cited by 3

COVID-19 ve Hipertansiyon

Taşkaldıran, I., & Bayraktaroğlu, T. (2020) · Turkish Journal of Diabetes and Obesity · doi:10.25048/tudod.752989 · Cited by 3

Role of Infl ammation and Oxidative Stress in the Development of Arterial Hypertension

Ясюкайть, Н. В., & Павлова, О. С. (2021) · Кардиология в Беларуси · doi:10.34883/pi.2021.13.4.009 · Cited by 3

Updates on the Pharmacology of Chloroquine against Coronavirus Disease 2019 (COVID-19): A Perspective on its Use in the General and Geriatric Population

Yao, X., Hou, Z., Cui, C., Zhang, M., Tu, S., Li, H., & Liu, D. (2020) · Current Drug Metabolism · doi:10.2174/1389200221666200711160440 · Cited by 3

What Kind of Evidence Is Needed to Dictate Practice Regarding Inhibitors of the Renin-Angiotensin System in COVID-19?

Elijovich, F., & Laffer, C. L. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.15712 · Cited by 3

RAAS Blockers and Region-Specific Variations in COVID-19 Outcomes: Findings from a Systematic Review and Meta-AnalysisPreprint

Kaur, U., Chakrabarti, S. S., & Patel, T. K. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3684465 · Cited by 3

From Foe to Friend in COVID-19: Renin-Angiotensin System Inhibitors

Kidde, J., & Sahebkar, A. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa629 · Cited by 3

Effect of Statins and Renin–Angiotensin–Aldosterone System Inhibitors on IL-6 Levels in COVID-19 Patients

Pereckaitė, L., Vagulienė, N., Vitkauskaitė, A., Vitkauskienė, A., & Urbonienė, D. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216414 · Cited by 2

Telmisartan reduces systemic inflammation and alters the renin-angiotensin system in mild COVID-19

Lu, A., Agsalda‐Garcia, M., Hu, W., Chester, C., Naik, A. A., Mitchell, B. I., Asante, I., Souza, S. A., Lian, K.-C., Zhang, Z., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-30304-x · Cited by 2

Molecular analysis of long COVID and new-onset diabetes mellitus: pathobiological relationships and current mechanistic views

Shitaye, G., Yizengaw, M. G., Mekonnen, Z., D’Abrosca, G., Fattorusso, R., Isernia, C., Amuamuta, A., & Malgieri, G. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1737894 · Cited by 4

The use of L-lysine aescinate in patients with novel coronavirus infection and acute cerebrovascular accident

Tokareva, E. R., & Gorbunov, V. (2023) · Vrach · doi:10.29296/25877305-2023-01-17 · Cited by 2

Considerations on the use of antihypertensive blockers of the renin-angiotensin system in adults and children in the face of the COVID-19 pandemic

Vázquez‐Cornejo, E. (2020) · Boletín Médico del Hospital Infantil de México · doi:10.24875/bmhim.20000158 · Cited by 2

Pengaruh penggunaan angiotensin converting enzyme inhibitor (ACEI) dan angiotensin receptor blocker (ARB) pada pasien coronavirus disease 2019 (covid-19) dengan hipertensi

Linelejan, B., Umboh, O. R. H., & Wantania, F. E. N. (2021) · e-CliniC · doi:10.35790/ecl.v9i1.31963 · Cited by 2

Coronavirus (COVID-19) infection - impact on cardiovascular system

Ahmed, M., Ball, P., & Morrissey, H. (2021) · Medicine and Pharmacy Reports · doi:10.15386/mpr-1900 · Cited by 2

Renin-angiotensin-aldosterone system inhibitors – a realm of confusion in COVID-19

Lazăr, A. M. (2021) · Journal of Ideas in Health · doi:10.47108/jidhealth.vol4.issspecial2.125 · Cited by 2

ABO-Rh Blood Types and Clinical Consequences of COVID-19 Infection

Turhan, A., Içten1, S., Ayazoğlu, T., Çağ, Y., Ankaralı, H. Ç., & Turhan, A. H. (2022) · Nigerian Journal of Clinical Practice · doi:10.4103/njcp.njcp_2042_21 · Cited by 2

Post-Exposure Prophylaxis for COVID-19: A Systematic Review

SeyedAlinaghi, S., Karimi, A., Pashaei, Z., Shobeiri, P., Janfaza, N., Behnezhad, F., Ghasemzadeh, A., Barzegary, A., Arjmand, G., Noroozi, A., et al. (2023) · Infectious Disorders - Drug Targets · doi:10.2174/1871526523666230413082721 · Cited by 2

Host Factors That Aggravate COVID-19 Pneumonia

Watanabe, S., Naito, Y., & Yamamoto, T. (2018) · doi:10.25107/ijfmpc-v1-id1011 · Cited by 8

Severity of SARS-COV-2 infection and angiotensin converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis

Oscanoa, T. J., Vidal, X., Carvajal, A., Amado, J., & Romero‐Ortuño, R. (2020) · Arterial Hypertension · doi:10.5603/ah.a2020.0013 · Cited by 2

Current and Future Challenges In Drug Therapeutics for Sars-Cov-2 Infection in Covid-19 Pandemic

Saksena, N. K. (2020) · American Journal of Biomedical Science & Research · doi:10.34297/ajbsr.2020.09.001374 · Cited by 2

Influenza A/H1N1 e COVID-19 no Brasil: impactos e diferenças epidemiológicas

Cândido, E. L., Costa, M. S., Júnior, J. G., & Moreira, M. R. C. (2020) · Revista de Epidemiologia e Controle de Infecção · doi:10.17058/reci.v10i3.15413 · Cited by 1

Bidirectional Relationship between COVID-19 and Diabetes

Khanam, R. (2021) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/jpbs.jpbs_508_20 · Cited by 3

Structure-based Molecular Docking in the Identification of Novel Inhibitors Targeting SARS-CoV-2 Main Protease

Miletić, V., Nikolić, P., & Kinkela, D. (2021) · International Convention on Information and Communication Technology, Electronics and Microelectronics · doi:10.23919/mipro52101.2021.9596660 · Cited by 2

Impact of RAAS Inhibitors on Clinical Outcome and Mortality in Patients With STEMI During the COVID-19 Era: A Multicenter Observational Study

Barbieri, L., Trabattoni, D., Stefanini, G. G., Vizzardi, E., Tumminello, G., Assanelli, E. M., Adamo, M., Pivato, C. A., Provenzale, G., Gentile, D., et al. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.792804 · Cited by 2

Therapeutic Approaches in COVID-19 Patients: The Role of the Renin-Angiotensin System

Ketabchi, F., & Jamzad, S. (2022) · Canadian Respiratory Journal · doi:10.1155/2022/8698825 · Cited by 2

Tăng huyết áp và Covid-19

-, N. Đ. H., & Minh, H. V. (2021) · Tạp chí Tim Mạch Học Việt Nam · doi:10.58354/jvc.98.2021.90 · Cited by 2

Current understanding of the origin, molecular biology and continuing evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Hakim, M. S., Annisa, L., Supriyati, E., Daniwijaya, E. W., Wibowo, R. A., Arguni, E., & Nuryastuti, T. (2020) · Journal of the Medical Sciences (Berkala Ilmu Kedokteran) · doi:10.19106/jmedscisi005203202005 · Cited by 2

COVID-19, diabetes, obesidad e hipertensión arterial: 60 días de pandemia en México

Ceballos-Cruz, Á., Pacheco-Pantoja, E. L., & Ferreyro‐Bravo, F. (2020) · Revista Mexicana de Endocrinología Metabolismo y Nutrición · doi:10.24875/rme.20000042 · Cited by 2

Susceptibility/manifestations of different age groups with various comorbidities to COVID-19 infection

John, A. R., Ha, F., & Zumwalt, M. A. (2020) · The Southwest Respiratory and Critical Care Chronicles · doi:10.12746/swrccc.v8i35.731 · Cited by 2

Atrial appendage angiotensin-converting enzyme-2, aging and cardiac surgical patients: a platform for understanding aging-related coronavirus disease-2019 vulnerabilities

Wang, H., Saha, A. K., Sun, X., Kon, N. D., Ferrario, C. M., & Groban, L. (2021) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000965 · Cited by 2

The Human-Covid Tango: Connecting the DotsPreprint

Hamdi, H., & Abdaldayem, E. (2020) · Preprints.org · doi:10.20944/preprints202004.0160.v1 · Cited by 2

Impact of hospitalised patients with COVID-19 taking Renin-Angiotensin-Aldosterone System inhibitors: a systematic review and meta-analysisPreprint

Baral, R., White, M., & Vassiliou, V. (2020) · medRxiv · doi:10.1101/2020.05.03.20089375 · Cited by 3

Letter to the editor: The role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in developing a COVID-19 comorbidity-based host risk score

Vavougios, G. D. (2020) · Critical Care · doi:10.1186/s13054-020-02903-9 · Cited by 2

In reply—Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers

Sanchis‐Gomar, F., Lavie, C. J., Pérez-Quilis, C., Henry, B. M., & Lippi, G. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.05.003 · Cited by 2

La práctica de la Cardiología ante la pandemia por COVID-19. Recomendaciones de la comunidad cardiológica mexicana

Sierra-Fernández, C., Alcocer-Gamba, M. A., & Buendía-Hernández, A. (2020) · Archivos de cardiología de México · doi:10.24875/acm.m20000072 · Cited by 2

Rebalance of the RAAS axes: the therapeutic strategy of COVID-19?Preprint

Huang, W., Meng, Y., Wu, P., & Li, X. (2020) · doi:10.22541/au.159050479.95287268 · Cited by 2

COVID-19 First and Delta Waves in Relation to ACEI, ARB, Influenza Vaccination, and Comorbidity in a North Metropolitan Barcelona Health ConsortiumPreprint

Juanes-González, M., Calderón-Valdiviezo, A., Losa-Puig, H., Valls-Foix, R., González-Salvador, M., León-Pérez, M., Pueyo-Antón, L., Lozano-Paz, C., Franco-Romero, M., Vidal‐Alaball, J., et al. (2021) · medRxiv · doi:10.1101/2021.11.17.21265440 · Cited by 2

Renin-angiotensin system inhibitors and severity of SARS-CoV-2 infection: a meta-analysisPreprint

Oscanoa, T. J., Vidal, X., Carvajal, A., & Romero-Ortuno, R. (2020) · doi:10.21203/rs.3.rs-29483/v1 · Cited by 2

Examination of the Relationship between the ABO Blood Group and Susceptibility to SARS-CoV-2 Infection Risk

Chrysanthakopoulos, N. A. (2022) · Insights in Blood Disorders · doi:10.33425/2771-9073.1004 · Cited by 1

Raw Vegan Diet in the Context of SARS-CoV-2 Infection

Kezele, T. G., Gulić, T., & Zagorac, G. B. (2024) · Medicina Fluminensis · doi:10.21860/medflum2024_313681 · Cited by 1

Angiotensin-Converting Enzyme Inhibition and/or Angiotensin Receptor Blockade Modulate Cytokine Profiles and Improve Clinical Outcomes in Experimental COVID-19 Infection

Santos, Y. D. S., Pagni, R. L., Gamon, T. H. M., de Azevedo, M. S. P., Darido, M. L. G., Oliveira, D. B. L., Durigon, E. L., Luvizotto, M. C. R., Ackerman, H. C., Marinho, C. R. F., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167663 · Cited by 1

Renin-angiotensin system inhibitors in management of hypertension during the COVID-19 pandemic.

Dworakowska, D., & Grossman, A. B. (2020) · PubMed · doi:10.26402/jpp.2020.2.01 · Cited by 12

Use of inhibitors of the renin‐angiotensin system in hypertensive patients and COVID‐19 severity: A systematic review and meta‐analysis

Barochiner, J., & Martínez, R. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13246 · Cited by 56

Comparison of Renin–Angiotensin–Aldosterone System Inhibitors with Other Antihypertensives in Association with Coronavirus Disease-19 Clinical Outcomes: Systematic Review and Meta-AnalysisPreprint

Bezabih, Y. M., Bezabih, A., Alamneh, E. A., Peterson, G. M., & Bezabhe, W. M. M. (2020) · Preprints.org · doi:10.20944/preprints202005.0392.v1

Effect of Renin-Angiotensin-Aldosterone System inhibitors on outcomes of COVID-19 patients with hypertension: Systematic review and Meta-analysisPreprint

Beressa, T. B., Sahilu, T., & Deyno, S. (2020) · medRxiv · doi:10.1101/2020.09.03.20187393 · Cited by 4

[Differences among renin-angiotensin system inhibitor drugs in prognosis of hypertense patients with COVID-19].

Caamaño, M. N., Rio, J. M., Nieto-Sandoval-Martín-de-la-Sierra, P., Águila‐Gordo, D., Mateo-Gómez, C., Rodríguez-Martínez, M., Salas-Bravo, D., & Piqueras‐Flores, J. (2022) · PubMed Central · doi:10.24875/acm.21000185